Synergistic Vaccine System for Enhanced Immunity Against SARS-CoV-2

Publication ID: 24-11857620_0008_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Vaccine System for Enhanced Immunity Against SARS-CoV-2,” Published Technical Disclosure No. 24-11857620_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857620_0008_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,620.

Summary of the Inventive Concept

A novel vaccine system integrating replication-defective adenovirus-delivered spike and nucleocapsid immunogens with cutting-edge technologies like AI, IoT, blockchain, and nanomaterials to induce robust immunity against SARS-CoV-2.

Background and Problem Solved

The original patent disclosed a method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid immunogens delivered by a replication-defective adenovirus. However, this approach has limitations in terms of tracking vaccine administration and efficacy, optimizing antigen presentation, and personalizing vaccine development. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful and efficient system.

Detailed Description of the Inventive Concept

The new inventive concept combines the replication-defective adenovirus-delivered spike and nucleocapsid immunogens with a blockchain-based tracking system for monitoring vaccine administration and efficacy. Additionally, AI-powered analytics optimize antigen presentation and immune response, while a nanomaterial-based adjuvant enhances immune response. An IoT-enabled platform monitors individual immune responses, and a machine learning algorithm predicts optimal vaccine formulations and dosing regimens. This synergistic system enables real-time monitoring of vaccine efficacy and personalized vaccine development.

Novelty and Inventive Step

The new claims introduce novel combinations of technologies, including blockchain-based tracking, AI-powered analytics, nanomaterial-based adjuvants, and IoT-enabled platforms, which are not obvious from the original patent. These integrations provide a non-obvious solution to the limitations of the original patent, enhancing the overall vaccine system.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include using different types of immunogens, adjuvants, or delivery systems. Additionally, the system could be adapted for use with other diseases or pathogens, or integrated with other technologies like CRISPR or gene editing.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the vaccine development and healthcare industries, particularly in the context of pandemics and emerging diseases. The system's ability to track vaccine administration and efficacy, optimize antigen presentation, and personalize vaccine development could revolutionize the field of vaccine development and improve public health outcomes.

CPC Classifications

Section	Class	Group
A	A61	A61K39/215
A	A61	A61K39/39
C	C12	C12N15/86
A	A61	A61K2039/545
A	A61	A61K2039/55505
A	A61	A61P31/14
C	C12	C12N2710/10343
C	C12	C12N2770/20022
C	C12	C12N2770/20034

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Vaccine development, immunology, and biotechnology, specifically focused on coronavirus vaccine design and delivery systems. Requires advanced knowledge of molecular biology, immunogen engineering, and vaccine formulation technologies

Person of Ordinary Skill (PHOSITA) Profile

A PhD-level researcher with expertise in virology, immunology, and vaccine development, familiar with adenovirus vector technologies, antigen engineering, and emerging biotechnology platforms

Obviousness Rationale

A PHOSITA would recognize that integrating digital technologies and advanced analytics with existing vaccine platforms represents a predictable extension of standard vaccine development practices. The core immunological mechanism from the source patent remains unchanged, with the PTD merely adding complementary tracking and optimization technologies. These technological additions would be considered routine improvements by a skilled practitioner seeking to enhance vaccine monitoring and personalization.

Obvious Combinations & Variations

Source Patent Element

Replication-defective adenovirus delivering spike and nucleocapsid immunogens

PTD Variation

Adding blockchain tracking and AI-powered analytics to vaccine administration

Obviousness Reasoning

Integrating digital tracking systems with biological technologies is a known technique in modern medical research, representing a predictable application of existing technological frameworks

Source Patent Element

Intranasal and injectable vaccine delivery methods

PTD Variation

IoT-enabled platform for monitoring individual immune responses

Obviousness Reasoning

Personalized medical monitoring is a standard approach in contemporary vaccine development, representing an obvious extension of existing clinical tracking methodologies

Source Patent Element

SARS-CoV-2 immunogen design using spike and nucleocapsid proteins

PTD Variation

Nanomaterial-based adjuvant for enhancing immune response

Obviousness Reasoning

Adjuvant technologies are well-known in vaccine development, and selecting nanomaterial-based systems represents a finite set of predictable design choices for improving immunogenicity

Source Patent Element

Vaccine composition for inducing mucosal immunity

PTD Variation

Machine learning algorithm for predicting optimal vaccine formulations

Obviousness Reasoning

Computational optimization of biological systems is a standard approach in biotechnology, representing an obvious application of computational techniques to existing vaccine development processes

35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. § 103, the variations disclosed in this publication would be considered obvious to a person having ordinary skill in the art at the time of invention, when viewed in light of US Patent 11857620. The incremental technological additions represent predictable combinations of known techniques in vaccine development and digital health monitoring, lacking the requisite non-obviousness for patent protection.

Original Patent Information

Patent Number	US 11,857,620
Title	Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
Assignee(s)	ImmunityBio, Inc.